58 – Streptococcus group A vaccines
Karen L. Kotloff
- pp 1169-1175
About:
The article was published on 2013-01-01 and is currently open access. It has received 1 citations till now. The article focuses on the topics: Streptococcus.read more
Citations
More filters
The Serological Differentiation of Pathogenic and Non-Pathogenic Strains of Hemolytie Streptococci from Parturient Women.
Rebecca C. Lancefield,R. Hare +1 more
TL;DR: The existence of two new serological groups of hemolytic streptococci, Groups F and G, is described, and the majority of strains isolated from the birth canal of women whose puerperium was afebrile were not members of Group A.
References
More filters
Journal ArticleDOI
The global burden of group A streptococcal diseases
TL;DR: The need to reinforce current control strategies, develop new primary prevention strategies, and collect better data from developing countries for most diseases is highlighted, as GAS is an important cause of morbidity and mortality.
Journal ArticleDOI
Pathogenesis of Group A Streptococcal Infections
TL;DR: Group A streptococci are model extracellular gram-positive pathogens responsible for pharyngitis, impetigo, rheumatic fever, and acute glomerulonephritis, and an emerging theme is the dichotomy between skin and throat strains in their epidemiology and genetic makeup.
Journal ArticleDOI
A serological differentiation of human and other groups of hemolytic streptococci.
TL;DR: Five strains of hemolytic streptococci isolated from man, other animals, milk, and cheese have been classified into five groups, which bear a definite relationship to the sources of the cultures, each being chemically distinct and ser specific in the individual groups.
Journal ArticleDOI
Streptococcal M protein: molecular design and biological behavior.
TL;DR: Many of the approaches described in the elucidation of the M-protein structure may be applied for characterizing similar molecules in other microbial systems.
Journal ArticleDOI
Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia.
Steven Black,Henry R. Shinefield,Stella Ling,John Hansen,Bruce Fireman,David Spring,Jack Noyes,Edwin Lewis,Paula Ray,Janelle Lee,Jill G. Hackell +10 more
TL;DR: The heptavalent CRM197 pneumococcal conjugate vaccine was given to infants at 2, 4, 6 and 12 to 15 months of age in a randomized, double blind trial and was effective in reducing the risk of pneumonia in young children.